{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:01:24Z","timestamp":1769695284658,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Implantable cardioverter-defibrillators (ICDs) are effective in detecting and treating ventricular arrhythmias. Studies on ICD therapy for different indications (primary and secondary prevention) and possible predictors of ICD therapy are limited. In this study, the incidence and type of ICD therapy were related to the indication and the underlying cardiac pathology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A\u00a0single-centre, retrospective and observational study was performed of 482\u00a0patients who underwent ICD implantation for primary (53.3%) or secondary prevention (46.7%) between 2015 and 2020\u202fat the Radboud University Medical Centre.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During a\u00a0median follow-up of 2.4\u00a0years (interquartile range 0.2\u20133.9), the occurrence of appropriate ICD therapy for primary versus secondary prevention was 9.7% and 27.6%, respectively (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001). Time to appropriate ICD therapy was significantly shorter in the secondary prevention group (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001). No difference in ICD therapy was seen for different underlying aetiologies. In the majority of cases (70%) ICD therapy was given for ventricular tachycardia (VT). The occurrence of adverse events (16.3% vs 17.3%, <jats:italic>p<\/jats:italic>\u202f=\u20090.772), hospitalisation for cardiovascular reasons (29.2% vs 35.1%, <jats:italic>p<\/jats:italic>\u202f=\u20090.559) and all-cause mortality (12.5% vs 11.6%, <jats:italic>p<\/jats:italic>\u202f=\u20090.763) were similar in both groups. Male gender (3.53, 95% confidence interval (CI) (1.003, 12.403), <jats:italic>p<\/jats:italic>\u202f=\u20090.049) and secondary prevention indication (4.90, 95% CI (1.495, 16.066), <jats:italic>p<\/jats:italic>\u202f=\u20090.009) were predictors of appropriate ICD therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The risk associated with appropriate ICD therapy is higher in secondary prevention patients, who have their first therapy within a\u00a0shorter time frame after device implantation. Rates of complications, hospitalisation and all-cause mortality are comparable. Future treatment options should target the prevention of ICD therapy, mainly by preventing the recurrence of VT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12471-023-01785-0","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T11:02:28Z","timestamp":1686913348000},"page":"348-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison and predictors of implantable cardioverter-defibrillator therapy for primary and secondary prevention"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-3098","authenticated-orcid":false,"given":"Reinder","family":"Evertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rypko","family":"Beukema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjoerd","family":"Westra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Meindersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"van Deursen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Vernooy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"1785_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.31083\/j.rcm.2021.01.207","volume":"22","author":"A Kumar","year":"2021","unstructured":"Kumar\u00a0A, Avishay\u00a0DM, Jones\u00a0CR, et\u00a0al. Sudden cardiac death: epidemiology, pathogenesis and management. Rev Cardiovasc Med. 2021;22:147\u201358.","journal-title":"Rev Cardiovasc Med"},{"issue":"34","key":"1785_CR2","first-page":"2281","volume":"2013","author":"M Brignole","year":"2013","unstructured":"Brignole\u00a0M, Auricchio\u00a0A, Baron-Esquivias\u00a0G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European society of cardiology (ESC). Developed in collaboration with the European heart rhythm association (EHRA). Eur Heart\u00a0J. 2013;34:2281\u2013329.","journal-title":"Eur Heart\u00a0J."},{"key":"1785_CR3","first-page":"760","volume":"17","author":"Y Konstantino","year":"2015","unstructured":"Konstantino\u00a0Y, Shafat\u00a0T, Novack\u00a0V, et\u00a0al. Incidence of implantable cardioverter defibrillator therapy and mortality in primary and secondary prevention of sudden cardiac death. Isr Med Assoc\u00a0J. 2015;17:760\u20133.","journal-title":"Isr Med Assoc\u00a0J."},{"key":"1785_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/europace\/euv188","volume":"18","author":"B Schaer","year":"2016","unstructured":"Schaer\u00a0B, K\u00fchne\u00a0M, Reichlin\u00a0T, et al. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a\u00a0secondary preventive implantable cardioverter-defibrillator indication. Europace. 2016;18:227\u201331.","journal-title":"Europace"},{"key":"1785_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/europace\/euq494","volume":"13","author":"GH van Welsenes","year":"2011","unstructured":"van Welsenes\u00a0GH, van Rees\u00a0JB, Borleffs\u00a0CJ, et al. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace. 2011;13:389\u201394.","journal-title":"Europace"},{"key":"1785_CR6","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.3346\/jkms.2020.35.e49","volume":"35","author":"MH Bae","year":"2020","unstructured":"Bae\u00a0MH, Cho\u00a0Y, Hwang\u00a0J, et al. Clinical impact of implantable cardioverter-defibrillator therapy and mortality prediction model for effective primary prevention in Korean patients. J\u00a0Korean Med Sci. 2020;35:e49.","journal-title":"J\u00a0Korean Med Sci."},{"key":"1785_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jacep.2018.01.013","volume":"4","author":"M de Riva","year":"2018","unstructured":"de Riva\u00a0M, Naruse\u00a0Y, Ebert\u00a0M, et\u00a0al. Targeting the hidden substrate unmasked by right ventricular extrastimulation improves ventricular tachycardia ablation outcome after myocardial infarction. JACC Clin Electrophysiol. 2018;4:316\u201327.","journal-title":"JACC Clin Electrophysiol."},{"key":"1785_CR8","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.jacep.2020.07.028","volume":"6","author":"J Fernandez-Armenta","year":"2020","unstructured":"Fernandez-Armenta\u00a0J, Soto-Iglesias\u00a0D, Silva\u00a0E, et al. Safety and outcomes of ventricular tachycardia substrate ablation during sinus rhythm: a\u00a0prospective multicenter registry. JACC Clin Electrophysiol. 2020;6:1435\u201348.","journal-title":"JACC Clin Electrophysiol."},{"key":"1785_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jacep.2017.12.005","volume":"4","author":"A Porta-Sanchez","year":"2018","unstructured":"Porta-Sanchez\u00a0A, Jackson\u00a0N, Lukac\u00a0P, et al. Multicenter study of ischemic ventricular tachycardia ablation with decrement-evoked potential (DEEP) mapping with extra stimulus. JACC Clin Electrophysiol. 2018;4:307\u201315.","journal-title":"JACC Clin Electrophysiol."},{"key":"1785_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jce.12565","volume":"26","author":"F Sacher","year":"2015","unstructured":"Sacher\u00a0F, Lim\u00a0HS, Derval\u00a0N, et\u00a0al. Substrate mapping and ablation for ventricular tachycardia: the LAVA approach. J\u00a0Cardiovasc Electrophysiol. 2015;26:464\u201371.","journal-title":"J\u00a0Cardiovasc Electrophysiol."},{"key":"1785_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1513614","volume":"375","author":"JL Sapp","year":"2016","unstructured":"Sapp\u00a0JL, Wells\u00a0GA, Parkash\u00a0R, et\u00a0al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N\u00a0Engl J Med. 2016;375:111\u201321.","journal-title":"Engl J Med"},{"key":"1785_CR12","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1161\/CIRCULATIONAHA.111.043216","volume":"125","author":"P Ja\u00efs","year":"2012","unstructured":"Ja\u00efs\u00a0P, Maury\u00a0P, Khairy\u00a0P, et al. Elimination of local abnormal ventricular activities: a\u00a0new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation. 2012;125:2184\u201396.","journal-title":"Circulation."}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-023-01785-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-023-01785-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-023-01785-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:20:21Z","timestamp":1692699621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-023-01785-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1785"],"URL":"https:\/\/doi.org\/10.1007\/s12471-023-01785-0","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"5 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.\u00a0Evertz, T.\u00a0van der Heijden, R.\u00a0Beukema, S.\u00a0Westra,E.\u00a0Meindersma, C.\u00a0van Deursen and K.\u00a0Vernooy declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}